You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Article info

Article menu

Download PDFPDF

Oral Plenary
Plenary V
IGCS20_1271
14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Free

Authors

Citation

Nishikawa N, Shoji T, Enomoto T, et al
14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
International Journal of Gynecologic Cancer 2020;30:A10-A11.

Publication history

  • First published November 13, 2020.
Online issue publication 
November 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.